UGA Research News Highlights Annate Bitherapeutics in Feature on Cancer Innovation

Annate Bitherapeutics is honored to be featured by UGA Research News in a March 17, 2026 story highlighting the company’s origins, scientific approach, and ongoing work to develop a new class of cancer therapeutics based on the innate human immune system. The feature spotlights the company’s leadership team—Eric DeJesus, PhD, Stephen Hajduk, PhD, and Michael Cipriano, PhD—and Annate’s mission to translate academic discovery into treatments with real impact for patients.

The article describes how Annate’s platform builds on foundational work at the University of Georgia to redirect a naturally occurring human defense mechanism toward cancer cells using bispecific antibodies. It also traces the personal and scientific motivations behind the company, including the experiences that shaped its focus on delivering more effective options for patients facing cancers such as multiple myeloma and other hard-to-treat diseases.

UGA Research News also highlights the realities of building a science-driven startup: generating strong data, refining the company’s message for investors and partners, and continuing to pursue the funding and collaborations needed to move the platform forward. Together, the story underscores Annate Bitherapeutics’ commitment to advancing innovative oncology therapies grounded in rigorous research and patient-centered purpose.

Read the full feature from UGA Research News: ‘A chance to ring the bell’: How a UGA startup is changing the fight against cancer